Published in Proc Natl Acad Sci U S A on November 20, 2002
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Viral membrane fusion. Nat Struct Mol Biol (2008) 8.54
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother (2006) 4.14
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev (2008) 2.88
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A (2003) 2.43
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med (2014) 2.22
HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med (2012) 2.18
Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol (2005) 2.05
N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol (2006) 1.97
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol (2004) 1.91
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol (2008) 1.84
Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc (2008) 1.84
Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med (2006) 1.83
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A (2005) 1.74
Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol (2005) 1.73
Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol (2008) 1.71
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol (2004) 1.69
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol (2005) 1.68
Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J Virol (2004) 1.68
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol (2005) 1.65
Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med (2008) 1.60
Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. Proc Natl Acad Sci U S A (2015) 1.59
Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun (2006) 1.58
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog (2007) 1.55
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol (2011) 1.55
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J Virol (2005) 1.53
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol (2005) 1.53
Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol (2004) 1.50
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem (2012) 1.48
Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling. J Virol (2007) 1.48
Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies (2005) 1.46
Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol (2004) 1.44
Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate. J Virol (2004) 1.44
Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol (2008) 1.43
Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol (2005) 1.42
Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A (2005) 1.36
A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol (2009) 1.34
Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol (2010) 1.33
Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol (2006) 1.33
Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane. Mol Biol Cell (2005) 1.32
Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol (2005) 1.30
HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo. J Virol (2011) 1.26
Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol (2007) 1.25
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology (2007) 1.21
Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol (2007) 1.20
Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J Virol (2009) 1.17
Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol (2004) 1.17
Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog (2009) 1.15
Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem (2008) 1.14
Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog (2009) 1.14
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J Virol (2007) 1.14
Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol (2004) 1.13
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol (2012) 1.13
Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol (2006) 1.13
Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology (2008) 1.11
HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120. J Virol (2012) 1.11
Viral entry inhibitors targeted to the membrane site of action. J Virol (2010) 1.10
Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci U S A (2008) 1.09
Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology (2004) 1.08
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology (2009) 1.07
A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol (2007) 1.05
Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation. J Virol (2009) 1.05
Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis. Clin Exp Immunol (2005) 1.05
CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol (2004) 1.04
Tropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS (2009) 1.03
Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J Virol (2006) 1.03
In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J Virol (2004) 1.03
A quantitative and kinetic fusion protein-triggering assay can discern distinct steps in the nipah virus membrane fusion cascade. J Virol (2010) 1.01
The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection. Virol J (2006) 1.01
CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women. J Acquir Immune Defic Syndr (2012) 1.01
HIV-1 induced bystander apoptosis. Viruses (2012) 1.01
Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J Virol (2009) 1.01
Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci (2008) 1.01
The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors. Retrovirology (2008) 1.00
Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis. Cell Mol Life Sci (2008) 1.00
HIV-1 Entry, Inhibitors, and Resistance. Viruses (2010) 1.00
Kinetic dependence of paramyxovirus entry inhibition. J Virol (2009) 1.00
Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother (2004) 1.00
An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations. J Mol Biol (2007) 0.99
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology (2011) 0.98
Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein. Retrovirology (2006) 0.98
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology (2006) 0.98
Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists. J Virol (2007) 0.97
Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry. Proc Natl Acad Sci U S A (2012) 0.97
R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch. J Virol (2008) 0.97
Flat clathrin lattices: stable features of the plasma membrane. Mol Biol Cell (2014) 0.96
Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains. J Virol (2013) 0.96
Solution structure of the monovalent lectin microvirin in complex with Man(alpha)(1-2)Man provides a basis for anti-HIV activity with low toxicity. J Biol Chem (2011) 0.96
Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol (2009) 0.96
Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100. J Virol (2008) 0.95
Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 10.27
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol (2000) 5.71
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A (1999) 4.61
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol (1998) 4.48
Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J Virol (1992) 3.53
The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med (1997) 3.36
Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol (2000) 2.95
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89
HIV-1 membrane fusion: targets of opportunity. J Cell Biol (2000) 2.84
The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J (1996) 2.21
HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry (2001) 2.07
Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol (1999) 2.02
Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains. J Virol (1999) 1.72
Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol (2002) 1.69
Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol (1999) 1.68
Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes. J Biol Chem (2001) 1.68
Cell-cell fusion assay to study role of chemokine receptors in human immunodeficiency virus type 1 entry. Methods Enzymol (1997) 1.61
Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother (2002) 1.49
A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors. Proc Natl Acad Sci U S A (2000) 1.45
Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr (2000) 1.41
Evaluation of current approaches to inhibit HIV entry. Curr Drug Targets Infect Disord (2002) 1.03
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog (2009) 4.04
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol (2002) 3.58
The HIV Env-mediated fusion reaction. Biochim Biophys Acta (2003) 3.37
Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS (2007) 3.26
Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med (2008) 3.20
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology (2003) 3.20
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol (2002) 2.93
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol (2006) 2.79
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology (2010) 2.55
Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol (2002) 2.46
The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A (2003) 2.43
Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol (2003) 2.42
Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol (2006) 2.41
Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J Exp Med (2009) 2.39
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol (2006) 2.34
Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog (2009) 2.29
Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol (2002) 2.23
Functional involvement of a novel Nedd4-like ubiquitin ligase on retrovirus budding. EMBO Rep (2002) 2.22
Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc Natl Acad Sci U S A (2006) 2.16
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
Virally induced CD4+ T cell depletion is not sufficient to induce AIDS in a natural host. J Immunol (2007) 2.01
N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. J Virol (2005) 2.00
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol (2005) 1.97
A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol (2002) 1.97
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Characterization of neutralizing antibodies to West Nile virus. Virology (2005) 1.81
Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood (2013) 1.80
Quantitative expression and virus transmission analysis of DC-SIGN on monocyte-derived dendritic cells. J Virol (2002) 1.78
Retroviral mRNA nuclear export elements regulate protein function and virion assembly. EMBO J (2004) 1.77
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol (2005) 1.75
Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol (2005) 1.73
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst (2009) 1.73
Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res (2009) 1.72
HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J Virol (2009) 1.69
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol (2004) 1.69
CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol (2002) 1.66
Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol (2002) 1.64
Depletion of CD4⁺ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J Clin Invest (2011) 1.62
M-PMV capsid transport is mediated by Env/Gag interactions at the pericentriolar recycling endosome. Traffic (2003) 1.58
Indeterminate and discrepant rapid HIV test results in couples' HIV testing and counselling centres in Africa. J Int AIDS Soc (2011) 1.55
Molecular mechanisms of HIV entry. Adv Exp Med Biol (2012) 1.55
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog (2007) 1.55
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol (2011) 1.55
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem (2006) 1.54
Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain. Biochemistry (2005) 1.52
HIV transmission. Cold Spring Harb Perspect Med (2012) 1.52
An infectious West Nile virus that expresses a GFP reporter gene. Virology (2005) 1.51
Human immunodeficiency virus type 2. J Gen Virol (2002) 1.50
Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog (2012) 1.50
Comparing antigenicity and immunogenicity of engineered gp120. J Virol (2005) 1.50
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50
The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol (2010) 1.49
A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo. PLoS Pathog (2010) 1.48
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol (2010) 1.47
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem (2002) 1.46
Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry (2007) 1.46
HIV: cell binding and entry. Cold Spring Harb Perspect Med (2012) 1.46
The M-PMV cytoplasmic targeting-retention signal directs nascent Gag polypeptides to a pericentriolar region of the cell. Traffic (2003) 1.45
Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol (2004) 1.44
Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol (2008) 1.41
Importance of the membrane-perturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion. J Virol (2008) 1.40
Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol (2009) 1.40